Goldport Capital
Investment Details
Investor Type
Venture Capital
Asset Class Focus
Venture Capital, Private Equity
Stage Focus
Early Stage, Seed, Series A, Series B
Geographical Focus
China
Industries Focus
- Healthcare
- Consumer Goods
- Biotechnology
- Advanced Manufacturing
- New Energy
Investment Size:
10,000,000 to 50,000,000 USD
Investor Details Founded: 2014
Goldport Capital is a Shenzhen-based venture capital firm specializing in early-stage investments in biotechnology and related sectors. The firm focuses on sectors such as advanced manufacturing, new energy, healthcare, and consumer goods.
Established in 2014, Goldport Capital has made 55 investments, with its most recent being in Rongxin New Materials on July 15, 2025. Notable exits include Microtech Medical. The firm's portfolio includes companies like CellOrigin Biotech, a company committed to iPSC-derived innate immune cell therapeutics.
Goldport Capital's investment strategy emphasizes sectors like biotechnology, healthcare, advanced manufacturing, new energy, and consumer goods. The firm has a history of leading investments in various funding rounds, including seed, Series A, and Series B stages. Its portfolio reflects a commitment to supporting innovative companies in these sectors, contributing to advancements in biotechnology and related industries.
Requirements
- Innovative biotechnology solutions
- Strong management teams
- Scalable business models
Contact
[Official Website Hidden]
[HQ Location Hidden]
Portfolio Companies
- CellOrigin Biotech
- Rongxin New Materials
- Yurucheng
- Zinc Core Titanium
- Yisite Biotech
- Chaoguang Micro
- Teyan Semiconductor
- Omnivision
- Depp CNC
- Fast Photonics
- Ruigu New Materials
Claim this Investor
Are you an official representative of Goldport Capital?
Claim this investor to update information, manage your profile, and get a verified seal.
Claim